Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 3 studies | 18% ± 2% |
Insufficient scRNA-seq data for expression of RBBP9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 892.14 | 1445 / 1445 | 100% | 28.44 | 183 / 183 |
| thymus | 100% | 1911.47 | 653 / 653 | 100% | 68.22 | 605 / 605 |
| brain | 100% | 833.82 | 2637 / 2642 | 100% | 34.16 | 705 / 705 |
| ovary | 100% | 982.77 | 180 / 180 | 100% | 27.19 | 429 / 430 |
| lung | 100% | 1126.27 | 578 / 578 | 100% | 29.50 | 1151 / 1155 |
| breast | 100% | 1013.82 | 459 / 459 | 100% | 38.67 | 1113 / 1118 |
| prostate | 100% | 986.61 | 245 / 245 | 99% | 24.68 | 499 / 502 |
| uterus | 100% | 1067.52 | 170 / 170 | 99% | 26.79 | 455 / 459 |
| bladder | 100% | 924.67 | 21 / 21 | 99% | 24.43 | 499 / 504 |
| stomach | 100% | 698.14 | 358 / 359 | 99% | 27.22 | 283 / 286 |
| intestine | 100% | 860.51 | 966 / 966 | 98% | 22.83 | 518 / 527 |
| kidney | 100% | 1369.07 | 89 / 89 | 98% | 36.47 | 880 / 901 |
| adrenal gland | 100% | 1921.80 | 258 / 258 | 96% | 19.90 | 220 / 230 |
| liver | 100% | 1014.89 | 226 / 226 | 96% | 22.28 | 388 / 406 |
| pancreas | 95% | 439.61 | 313 / 328 | 99% | 18.90 | 176 / 178 |
| skin | 100% | 1531.13 | 1809 / 1809 | 93% | 23.30 | 440 / 472 |
| adipose | 100% | 1000.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 1255.32 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 100% | 635.05 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 31.44 | 45 / 45 |
| heart | 91% | 415.46 | 781 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 16.70 | 26 / 29 |
| muscle | 83% | 268.86 | 663 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 56% | 543.18 | 517 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 53% | 6.01 | 42 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0009624 | Biological process | response to nematode |
| GO_0010628 | Biological process | positive regulation of gene expression |
| GO_0060510 | Biological process | type II pneumocyte differentiation |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0016787 | Molecular function | hydrolase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | RBBP9 |
| Protein name | Serine hydrolase RBBP9 (EC 3.-.-.-) (B5T-overexpressed gene protein) (Protein BOG) (Retinoblastoma-binding protein 10) (RBBP-10) (Retinoblastoma-binding protein 9) (RBBP-9) |
| Synonyms | BOG RBBP10 |
| Description | FUNCTION: Serine hydrolase whose substrates have not been identified yet . May negatively regulate basal or autocrine TGF-beta signaling by suppressing SMAD2-SMAD3 phosphorylation . May play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-beta through interaction with RB1 and the subsequent displacement of E2F1 . . |
| Accessions | ENST00000337227.9 [O75884-1] O75884 |